Pharmacotherapy for treatment-resistant schizophrenia

Código QR

Pharmacotherapy for treatment-resistant schizophrenia

Meghan E Mcilwain1,2, Jeff Harrison1, Amanda J Wheeler1,3, Bruce R Russell1,21School of Pharmacy, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; 2Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/36b5e466ed7f4db5b9ccd890eec48990
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Role of aripiprazole in treatment-resistant schizophrenia
por: Mossaheb N, et al.
Publicado: (2012)

Pharmacotherapy of panic disorder
por: Charles B Pull, et al.
Publicado: (2008)

Measurement of treatment adherence with antipsychotic agents in patients with schizophrenia
por: Xinhua&nbsp;S Ren, et al.
Publicado: (2009)

Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent?
por: Maurizio Pompili, et al.
Publicado: (2008)

Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
por: Hongyan Zhang, et al.
Publicado: (2011)

Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia
por: Terzić T, et al.
Publicado: (2015)

Profile of blonanserin for the treatment of schizophrenia
por: Tenjin T, et al.
Publicado: (2013)

Role of sublingual asenapine in treatment of schizophrenia
por: Citrome L
Publicado: (2011)

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
por: Srihari Gopal, et al.
Publicado: (2011)

Profile of minocycline and its potential in the treatment of schizophrenia
por: Zhang L, et al.
Publicado: (2014)

Towards a framework for treatment effectiveness in schizophrenia
por: Juckel G, et al.
Publicado: (2014)

Atypical antipsychotics in the treatment of early-onset schizophrenia
por: Hrdlicka M, et al.
Publicado: (2015)

Augmentation with antidepressants in schizophrenia treatment: benefit or risk
por: Mao YM, et al.
Publicado: (2015)

Once-monthly paliperidone injection for the treatment of schizophrenia
por: Delia Bishara
Publicado: (2010)

Yokukansan and its ingredients as possible treatment options for schizophrenia
por: Yu CH, et al.
Publicado: (2014)

Persistent suicide risk in clinically improved schizophrenia patients: challenge of the suicidal dimension
por: Amresh Shrivastava, et al.
Publicado: (2010)

Psychosurgery for schizophrenia: history and perspectives
por: Soares MS, et al.
Publicado: (2013)

Tobacco smoking in treatment-resistant schizophrenia patients is associated with impaired cognitive functioning, more severe negative symptoms, and poorer social adjustment
por: Iasevoli F, et al.
Publicado: (2013)

Review of risperidone for the treatment of pediatric and adolescent bipolar disorder and schizophrenia
por: Jeffrey R Bishop, et al.
Publicado: (2008)

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments
por: Chien WT, et al.
Publicado: (2013)

An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia
por: Hirano J, et al.
Publicado: (2013)

Recurrent schizophrenia-like psychosis as first manifestation of epilepsy: a diagnostic challenge in neuropsychiatry
por: Willem MA Verhoeven, et al.
Publicado: (2010)

Soccer practice as an add-on treatment in the management of individuals with a diagnosis of schizophrenia
por: Battaglia G, et al.
Publicado: (2013)

The utility of novel outcome measures in a naturalistic evaluation of schizophrenia treatment
por: Tompsett T, et al.
Publicado: (2018)

Quality of life of patients with schizophrenia treated in foster home care and in outpatient treatment
por: Mihanović M, et al.
Publicado: (2015)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
por: Rosaria Di Lorenzo, et al.
Publicado: (2010)

Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
por: Mario Louz&atilde;, et al.
Publicado: (2010)

Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar&nbsp;I disorder
por: Delia Bishara, et al.
Publicado: (2009)

Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia
por: Ascher-Svanum H, et al.
Publicado: (2012)

Combination treatment with risperidone long-acting injection and psychoeducational approaches for preventing relapse in schizophrenia
por: Zhao Y, et al.
Publicado: (2013)

Movement disorder profile and treatment outcomes in a one-year study of patients with schizophrenia
por: Chen L, et al.
Publicado: (2013)

The cost of schizophrenia in Japan
por: Sado M, et al.
Publicado: (2013)

Jumping to conclusions in schizophrenia
por: Evans SL, et al.
Publicado: (2015)

Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
por: Azekawa T, et al.
Publicado: (2011)

Is quetiapine suitable for treatment of acute schizophrenia with catatonic stupor? A case series of 39 patients
por: Yoshimura B, et al.
Publicado: (2013)

Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia
por: Kaneda A, et al.
Publicado: (2013)

Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
por: Zhu W, et al.
Publicado: (2014)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
por: Ascher-Svanum H, et al.
Publicado: (2014)

Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients
por: Ann E Maloney, et al.
Publicado: (2010)

Erratum:&nbsp;An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat, 4: 967&ndash;976
por: Colombo GL, et al.
Publicado: (2009)